ENTRADA THERAPEUTICS INC. - COMMON STOCK

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

21 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

29 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

10 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

01 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

06 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2023 Financial Results

10 May 2023 07:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

04 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

29 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

06 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

27 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

09 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

19 Dec 2022 16:30:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

22 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

30 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

11 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

04 Aug 2022 07:00:03 By Nasdaq GlobeNewswire